Journal Article

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic

Xanthopoulidis, George, Sazakli, Eleni, Gavrilaki, Eleni, Pappa, Vassiliki, Terpos, Evangelos, Bouchla, Anthi, Kioumi, Anna, Labropoulou, Vassiliki, Panayiotidis, Panayiotis, Zikos, Panagiotis, Diamantopoulos, Panagiotis, Liapi, Dimitra, Karmas, Panagiotis, Vagia, Maria, Chandrinou, Eleni, Pagoni, Maria, Kotsopoulou, Maria, Viniou, Nora-Athina, Hatzimichael, Eleftheria, Katodritou, Eirini, Barmparousi, Despina, Kaiafa, Georgia, Symeonidis, Argiris, Dimou, Maria, Dalekou-Tsolakou, Maria, Palla, Katerina, Galanopoulos, Athanasios, Kartassis, Zafiris, Vassilopoulos, George, Pontikoglou, Charalampos, Kotsianidis, Ioannis, Vlachaki, Efthymia, Kourakli, Alexandra, Lazaris, Vasileios, Papoutselis, Menelaos, Michali, Evridiki, Vassilakopoulos, Theodoros P, Assimakopoulou, Theodora

2025

Overview

Lenalidomide has been approved for the treatment of transfusion-dependent patients with lower-risk MDS, exhibiting the del(5)q cytogenetic abnormality. Only sporadic cases, not thoroughly analyzed, describe information on lenalidomide treatment to patients with additional cytogenetic abnormalities, over del(5)q, or to patients with del(5)q and an excess of marrow blasts. Results from a harvest of 238 patients registered in the Greek National MDS Registry have shown that lenalidomide may be effective, not only in the del(5)q syndrome, as is described in previous MDS treatment recommendations and guidelines, but also in other MDS patients exhibiting del(5)q alone or with one additional cytogenetic abnormality, irrespective of BM blast cell percentage, a finding implying that in these patient groups, the dominant disease pathophysiology is governed by the presence of the del(5)q clone.

• Publisher: MDPI AG